{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:42:25Z","timestamp":1781592145281,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31 HL151160"],"award-info":[{"award-number":["F31 HL151160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA220002"],"award-info":[{"award-number":["R01 CA220002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nilotinib is a highly effective treatment for chronic myeloid leukemia but has been consistently associated with the development of nilotinib-induced arterial disease (NAD) in a subset of patients. To date, which cell types mediate this effect and whether NAD results from on-target mechanisms is unknown. We utilized human induced pluripotent stem cells (hiPSCs) to generate endothelial cells and vascular smooth muscle cells for in vitro study of NAD. We found that nilotinib adversely affects endothelial proliferation and migration, in addition to increasing intracellular nitric oxide. Nilotinib did not alter endothelial barrier function or lipid uptake. No effect of nilotinib was observed in vascular smooth muscle cells, suggesting that NAD is primarily mediated through endothelial cells. To evaluate whether NAD results from enhanced inhibition of ABL1, we generated multiple ABL1 knockout lines. The effects of nilotinib remained unchanged in the absence of ABL1, suggesting that NAD results from off- rather than on-target signaling. The model established in the present study can be applied to future mechanistic and patient-specific pharmacogenomic studies.<\/jats:p>","DOI":"10.1038\/s41598-024-57686-8","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T10:02:25Z","timestamp":1711447345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1"],"prefix":"10.1038","volume":"14","author":[{"given":"Emily A.","family":"Pinheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"DeKeyser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadav","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Burridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"57686_CR1","first-page":"2343","volume":"61","author":"E Laurent","year":"2001","unstructured":"Laurent, E., Talpaz, M., Kantarjian, H. & Kurzrock, R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res. 61, 2343\u20132355 (2001).","journal-title":"Cancer Res."},{"key":"57686_CR2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251\u20132259 (2010).","journal-title":"N. Engl. J. Med."},{"key":"57686_CR3","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus, A. et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30, 1044\u20131054 (2016).","journal-title":"Leukemia"},{"key":"57686_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian, H. M. et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35, 440\u2013453 (2021).","journal-title":"Leukemia"},{"key":"57686_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129\u2013141 (2005).","journal-title":"Cancer Cell"},{"key":"57686_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/ATVBAHA.118.312315","volume":"39","author":"X Li","year":"2019","unstructured":"Li, X. et al. Ponatinib combined with rapamycin causes regression of murine venous malformation. Arterioscler. Thromb. Vasc. Biol. 39, 496\u2013512 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"57686_CR7","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi, J. J. & Deininger, M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid Leukemia. J. Clin. Oncol. 33, 4210\u20134218 (2015).","journal-title":"J. Clin. Oncol."},{"key":"57686_CR8","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic, E. et al. Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site. Leukemia 31, 2388\u20132397 (2017).","journal-title":"Leukemia"},{"key":"57686_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","volume":"599","author":"E Day","year":"2008","unstructured":"Day, E. et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur. J. Pharmacol. 599, 44\u201353 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"57686_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1083\/jcb.201412052","volume":"209","author":"I Tabas","year":"2015","unstructured":"Tabas, I., Garc\u00eda-Carde\u00f1a, G. & Owens, G. K. Recent insights into the cellular biology of atherosclerosis. J. Cell Biol. 209, 13\u201322 (2015).","journal-title":"J. Cell Biol."},{"key":"57686_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","volume":"60","author":"A Gover-Proaktor","year":"2019","unstructured":"Gover-Proaktor, A. et al. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma 60, 189\u2013199 (2019).","journal-title":"Leuk Lymphoma"},{"key":"57686_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","volume":"5","author":"MG Pouwer","year":"2018","unstructured":"Pouwer, M. G. et al. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. Front. Cardiovasc. Med. 5, 55 (2018).","journal-title":"Front. Cardiovasc. Med."},{"key":"57686_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge, P. W. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547\u2013556 (2016).","journal-title":"Nat. Med."},{"key":"57686_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","volume":"145","author":"T Magdy","year":"2022","unstructured":"Magdy, T. et al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. Circulation 145, 279\u2013294 (2022).","journal-title":"Circulation"},{"key":"57686_CR15","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","volume":"28","author":"T Magdy","year":"2021","unstructured":"Magdy, T. et al. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell 28, 2076-2089.e2077 (2021).","journal-title":"Cell Stem Cell"},{"key":"57686_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.stem.2020.04.018","volume":"27","author":"T Toyohara","year":"2020","unstructured":"Toyohara, T. et al. Patient hiPSCs identify vascular smooth muscle arylacetamide deacetylase as protective against atherosclerosis. Cell Stem Cell 27, 147-157.e147 (2020).","journal-title":"Cell Stem Cell"},{"key":"57686_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1021\/acs.chemrestox.9b00363","volume":"33","author":"PH Chu","year":"2020","unstructured":"Chu, P. H. et al. Stem cell-derived endothelial cell model that responds to tobacco smoke like primary endothelial cells. Chem. Res. Toxicol. 33, 751\u2013763 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"57686_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharep.2015.05.024","volume":"68","author":"J Gacic","year":"2016","unstructured":"Gacic, J. et al. Imatinib reduces cholesterol uptake and matrix metalloproteinase activity in human THP-1 macrophages. Pharmacol. Rep. 68, 1\u20136 (2016).","journal-title":"Pharmacol. Rep."},{"key":"57686_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles, F. J. et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia 27, 1310\u20131315 (2013).","journal-title":"Leukemia"},{"key":"57686_CR20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/jcmm.12825","volume":"20","author":"YN Zhang","year":"2016","unstructured":"Zhang, Y. N. et al. Phenotypic switching of vascular smooth muscle cells in the \u201cnormal region\u201d of aorta from atherosclerosis patients is regulated by miR-145. J. Cell. Mol. Med. 20, 1049\u20131061 (2016).","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"57686_CR21","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/dta.3349","volume":"15","author":"M Caruso","year":"2022","unstructured":"Caruso, M. et al. Comparative assessment of electronic nicotine delivery systems aerosol and cigarette smoke on endothelial cell migration: The Replica Project. Drug Test Anal. 15(10), 1164\u20131174 (2022).","journal-title":"Drug Test Anal."},{"key":"57686_CR22","doi-asserted-by":"publisher","first-page":"C857","DOI":"10.1152\/ajpcell.00406.2019","volume":"318","author":"WL Xue","year":"2020","unstructured":"Xue, W. L. et al. Hydrogen sulfide rescues high glucose-induced migration dysfunction in HUVECs by upregulating miR-126-3p. Am. J. Physiol. Cell Physiol. 318, C857-c869 (2020).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"57686_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ccc.2019.12.009","volume":"36","author":"AR Cyr","year":"2020","unstructured":"Cyr, A. R., Huckaby, L. V., Shiva, S. S. & Zuckerbraun, B. S. Nitric oxide and endothelial dysfunction. Crit. Care Clin. 36, 307\u2013321 (2020).","journal-title":"Crit. Care Clin."},{"key":"57686_CR24","doi-asserted-by":"publisher","first-page":"e0122398","DOI":"10.1371\/journal.pone.0122398","volume":"10","author":"M Gonz\u00e1lez","year":"2015","unstructured":"Gonz\u00e1lez, M. et al. Insulin reverses D-glucose-increased nitric oxide and reactive oxygen species generation in human umbilical vein endothelial cells. PLoS ONE 10, e0122398 (2015).","journal-title":"PLoS ONE"},{"key":"57686_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00210-012-0794-3","volume":"385","author":"A Joshi","year":"2012","unstructured":"Joshi, A. & Woodman, O. L. Increased nitric oxide activity compensates for increased oxidative stress to maintain endothelial function in rat aorta in early type 1 diabetes. Naunyn Schmiedebergs Arch. Pharmacol. 385, 1083\u20131094 (2012).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"57686_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41569-019-0227-9","volume":"16","author":"GL Basatemur","year":"2019","unstructured":"Basatemur, G. L., J\u00f8rgensen, H. F., Clarke, M. C. H., Bennett, M. R. & Mallat, Z. Vascular smooth muscle cells in atherosclerosis. Nat. Rev. Cardiol. 16, 727\u2013744 (2019).","journal-title":"Nat. Rev. Cardiol."},{"key":"57686_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/cancers14020413","volume":"14","author":"M Sasaki","year":"2022","unstructured":"Sasaki, M. et al. Introduction of mutant GNAQ into endothelial cells induces a vascular malformation phenotype with therapeutic response to imatinib. Cancers (Basel) 14, 413 (2022).","journal-title":"Cancers (Basel)"},{"key":"57686_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.13346","volume":"169","author":"N Gunnarsson","year":"2015","unstructured":"Gunnarsson, N. et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br. J. Haematol. 169, 683\u2013688 (2015).","journal-title":"Br. J. Haematol."},{"key":"57686_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger, K. J. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am. J. Hematol. 86, 533\u2013539 (2011).","journal-title":"Am. J. Hematol."},{"key":"57686_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.stem.2017.03.017","volume":"20","author":"EE Pashos","year":"2017","unstructured":"Pashos, E. E. et al. Large, diverse population cohorts of hiPSCs and derived hepatocyte-like cells reveal functional genetic variation at blood lipid-associated loci. Cell Stem Cell 20, 558-570.e510 (2017).","journal-title":"Cell Stem Cell"},{"key":"57686_CR31","doi-asserted-by":"publisher","first-page":"dev146621","DOI":"10.1242\/dev.146621","volume":"147","author":"M Jakab","year":"2020","unstructured":"Jakab, M. & Augustin, H. G. Understanding angiodiversity: Insights from single cell biology. Development 147, dev146621 (2020).","journal-title":"Development"},{"key":"57686_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.stemcr.2019.12.007","volume":"14","author":"HH Kuo","year":"2020","unstructured":"Kuo, H. H. et al. Negligible-cost and weekend-free chemically defined human iPSC culture. Stem Cell Rep. 14, 256\u2013270 (2020).","journal-title":"Stem Cell Rep."},{"key":"57686_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"57686_CR34","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1182\/blood-2003-07-2315","volume":"103","author":"JB Kearney","year":"2004","unstructured":"Kearney, J. B., Kappas, N. C., Ellerstrom, C., DiPaola, F. W. & Bautch, V. L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 103, 4527\u20134535 (2004).","journal-title":"Blood"},{"key":"57686_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymeth.2015.12.012","volume":"101","author":"F Oceguera-Yanez","year":"2016","unstructured":"Oceguera-Yanez, F. et al. Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives. Methods 101, 43\u201355 (2016).","journal-title":"Methods"},{"key":"57686_CR36","first-page":"103","volume":"341","author":"P Ngo","year":"2006","unstructured":"Ngo, P., Ramalingam, P., Phillips, J. A. & Furuta, G. T. Collagen gel contraction assay. Methods Mol. Biol. 341, 103\u2013109 (2006).","journal-title":"Methods Mol. Biol."},{"key":"57686_CR37","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkt214","volume":"41","author":"Y Liao","year":"2013","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote. Nucl. Acids Res. 41, e108 (2013).","journal-title":"Nucl. Acids Res."},{"key":"57686_CR38","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57686-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57686-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57686-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T10:08:25Z","timestamp":1711447705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57686-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["57686"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-57686-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7123"}}